## Ethyl pyruvate

MedChemExpress

®

Cat. No.:	HY-Y1362		
CAS No.:	617-35-6		
Molecular Formula:	$C_{5}H_{8}O_{3}$		
Molecular Weight:	116.12		
Target:	Autophagy;	; Apoptos	is; Pyroptosis; NF-κB
Pathway:	Autophagy;	; Apoptos	is; Immunology/Inflammation; NF-кВ
Storage:	Pure form	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

### SOLVENT & SOLUBILITY

	DMSO : 100 mg/mL (8	61.18 mM; Need ultrasonic)			
		Solvent Mass Concentration	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	8.6118 mL	43.0589 mL	86.1178 mL
		5 mM	1.7224 mL	8.6118 mL	17.2236 mL
		10 mM	0.8612 mL	4.3059 mL	8.6118 mL

<b>BIOLOGICAL ACT</b>	IVITY
Description	Ethyl pyruvate is a simple derivative of the endogenous metabolite pyruvate. Ethyl pyruvate is an HMGB1 release inhibitor. Ethyl pyruvate can induce apoptosis by autophagy. Ethyl pyruvate has anti-inflammatory, antioxidant and anti-tumor activity. Ethyl pyruvate can be used in the study of neurodegenerative diseases such as Alzheimer's and Parkinson's disease [1][2][3][4][5].
In Vitro	Ethyl pyruvate (10 mM, 1 h) has no toxic effect on N9 microglial cells in the range of 1-10 mM. The activation of microglia NLRP3 inflammasome is decreased by inhibiting the HMGB1/ NF-κB /miR-223 signaling pathway <sup>[2]</sup> . Ethyl pyruvate (10-40 mM, 6, 24 h) induces apoptosis in MC38 cells <sup>[3]</sup> . Ethyl pyruvate (5-15 mM, 2 h) has an IC <sub>50</sub> value of 28.83 mM on mouse peritoneal macrophages. Endotoxemia and sepsis are prevented by inhibiting caspase-11-dependent pyroptosis <sup>[4]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay <sup>[2]</sup>

# Product Data Sheet

Cell Line:	N9 microglial
Concentration:	1-100 mM
Incubation Time:	1 h
Result:	Did not show cytotoxic effects in the range of 1–10 mM.
Western Blot Analysis <sup>[2]</sup>	
Cell Line:	N9 microglial
Concentration:	10 mM
Incubation Time:	1 h
Result:	Suppressed LPS (HY-D1056)- and ATP (HY-B2176)-induced IL-1β and IL-18 protein and mRNA levels. Reduced NLRP3, Caspase-1, and ASC Specks. Reduced NF-κB activation and HMGB1 expression level.
Apoptosis Analysis <sup>[3]</sup>	
Cell Line:	MC38
Concentration:	10, 20, 40 mM
Incubation Time:	6, 24 h
Result:	
Ethyl pyruvate (80 mg/k model <sup>[3]</sup> . Ethyl pyruvate (2 or 40 r rat model of paraquat ir MCE has not independe	g intraperitoneal injection for 9 consecutive days) inhibits tumor growth in a mouse liver tumor mg/kg, intraperitoneal injection) has reduced lipid peroxidation and anti-inflammatory effects i ntoxication <sup>[5]</sup> . ntly confirmed the accuracy of these methods. They are for reference only.
Ethyl pyruvate (80 mg/k model <sup>[3]</sup> . Ethyl pyruvate (2 or 40 r rat model of paraquat ir MCE has not independe Animal Model:	rg intraperitoneal injection for 9 consecutive days) inhibits tumor growth in a mouse liver tumor mg/kg, intraperitoneal injection) has reduced lipid peroxidation and anti-inflammatory effects i ntoxication <sup>[5]</sup> . ntly confirmed the accuracy of these methods. They are for reference only. Liver tumor model in mice <sup>[3]</sup>
Ethyl pyruvate (80 mg/k model <sup>[3]</sup> . Ethyl pyruvate (2 or 40 r rat model of paraquat ir MCE has not independe	rg intraperitoneal injection for 9 consecutive days) inhibits tumor growth in a mouse liver tumor mg/kg, intraperitoneal injection) has reduced lipid peroxidation and anti-inflammatory effects i ntoxication <sup>[5]</sup> . Intly confirmed the accuracy of these methods. They are for reference only. Liver tumor model in mice <sup>[3]</sup> 80 mg/kg
Ethyl pyruvate (80 mg/k model <sup>[3]</sup> . Ethyl pyruvate (2 or 40 r rat model of paraquat ir MCE has not independe Animal Model: Dosage:	rg intraperitoneal injection for 9 consecutive days) inhibits tumor growth in a mouse liver tumor mg/kg, intraperitoneal injection) has reduced lipid peroxidation and anti-inflammatory effects i ntoxication <sup>[5]</sup> . ntly confirmed the accuracy of these methods. They are for reference only. Liver tumor model in mice <sup>[3]</sup> 80 mg/kg i.p., 30 min before tumor injection and daily up to 9 days and daily from 7 to 10 days aft
Ethyl pyruvate (80 mg/k model <sup>[3]</sup> . Ethyl pyruvate (2 or 40 r rat model of paraquat ir MCE has not independe Animal Model: Dosage: Administration:	ntly confirmed the accuracy of these methods. They are for reference only.    Liver tumor model in mice <sup>[3]</sup> 80 mg/kg   i.p., 30 min before tumor injection and daily up to 9 days and daily from 7 to 10 days after infusion of tumor cells.   Decreased innate immune cells (NK cells, monocytes) and T and B cell lymphocytic infiltrates.
Ethyl pyruvate (80 mg/k model <sup>[3]</sup> . Ethyl pyruvate (2 or 40 r rat model of paraquat ir MCE has not independe Animal Model: Dosage: Administration: Result:	rg intraperitoneal injection for 9 consecutive days) inhibits tumor growth in a mouse liver tumor mg/kg, intraperitoneal injection) has reduced lipid peroxidation and anti-inflammatory effects in ntoxication <sup>[5]</sup> . ntly confirmed the accuracy of these methods. They are for reference only. Liver tumor model in mice <sup>[3]</sup> 80 mg/kg i.p., 30 min before tumor injection and daily up to 9 days and daily from 7 to 10 days after infusion of tumor cells. Decreased innate immune cells (NK cells, monocytes) and T and B cell lymphocytic infiltrates. Inhibited the release of HMBG1.
Ethyl pyruvate (80 mg/k model <sup>[3]</sup> . Ethyl pyruvate (2 or 40 r rat model of paraquat ir MCE has not independe Animal Model: Dosage: Administration: Result: Animal Model:	sg intraperitoneal injection for 9 consecutive days) inhibits tumor growth in a mouse liver tumor ng/kg, intraperitoneal injection) has reduced lipid peroxidation and anti-inflammatory effects in ntoxication <sup>[5]</sup> . ntly confirmed the accuracy of these methods. They are for reference only. Liver tumor model in mice <sup>[3]</sup> 80 mg/kg i.p., 30 min before tumor injection and daily up to 9 days and daily from 7 to 10 days after infusion of tumor cells. Decreased innate immune cells (NK cells, monocytes) and T and B cell lymphocytic infiltrates. Inhibited the release of HMBG1.

In Vivo

Decreased NO concentrations significantly at 6 h and GSH concentrations in the lung.

### **CUSTOMER VALIDATION**

- Cell Death Dis. 2019 Sep 26;10(10):724.
- Life Sci. 2021 Jan 5;118987.
- J Pharm Pharmacol. 2023 Mar 25;rgad021.
- PeerJ. August 4, 2022.
- Research Square Preprint. 2021 Jul.

See more customer validations on www.MedChemExpress.com

#### REFERENCES

[1]. Liang X, et al. Ethyl pyruvate administration inhibits hepatic tumor growth. J Leukoc Biol. 2009 Sep;86(3):599-607.

[2]. Qiu X, et al. Ethyl pyruvate confers protection against endotoxemia and sepsis by inhibiting caspase-11-dependent cell pyroptosis. Int Immunopharmacol. 2020 Jan;78:106016.

[3]. Lee J, et al. Protective effects of ethyl pyruvate treatment on paraquat-intoxicated rats. Hum Exp Toxicol. 2008 Jan;27(1):49-54.

[4]. Fink MP. Ethyl pyruvate: a novel anti-inflammatory agent. J Intern Med. 2007 Apr;261(4):349-62.

[5]. Olcum M, Tufekci KU, Durur DY, et al. Ethyl Pyruvate Attenuates Microglial NLRP3 Inflammasome Activation via Inhibition of HMGB1/NF-κB/miR-223 Signaling. Antioxidants (Basel). 2021;10(5):745.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA